Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Not yet recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Lymphoid 1 Head & Neck 1 Dermatologic 1 Breast 1

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 87 Cyclophosphamide 67 Capecitabine 67 Paclitaxel 64 Docetaxel 58 Fulvestrant 52 Letrozole 50 Carboplatin 42 pembrolizumab 41 Lapatinib 38 Doxorubicin 36 Anastrozole 32 Vinorelbine 31 Bevacizumab 31 exemestane 28 Tamoxifen 25 Gemcitabine 25 Albumin-Bound Paclitaxel 25 Radiotherapy 21 Taxes 19 atezolizumab 18 pertuzumab 17 Everolimus 17 130-nm albumin-bound paclitaxel 17 Epirubicin 16 palbociclib 15 Magnetic Resonance Spectroscopy 15 eribulin 14 Ado-Trastuzumab Emtansine 14 Goserelin 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Injections, Subcutaneous × Breast × Clear all

NCT04675827 2024-12-04

Decrescendo

Jules Bordet Institute

Phase 2 Terminated

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡